Our network focuses on overcoming 3 major barriers to effective translation, especially in diseases characterized by complexity and neurodiversity. These challenges stem from evaluating potential treatments against overly broad disease categories and simplistic models: 

1. The extrapolation from animal models often fails to translate effectively to humans due to their reductionistic approach, and translational concerns are insufficiently considered during study design and interpretation.
2. Treatment targets and methods frequently misalign with patients’ values because patient-relevant outcomes are incorporated too late in the research process.
3. Treatment regimens for multi-component chronic conditions lack robust models for personalization, as they go beyond the traditional “magic bullet” approach of discovery and evaluation.